Population
Colo-205 xenograft model
Design
Preclinical
Authors
Loading...
Warrants clinical trials before any use; extends preclinical antiangiogenic combination data in xenografts.
Ang2-specific CovX-Bodies demonstrate significant tumor growth inhibition and antiangiogenic effects in a preclinical xenograft model, both alone and in combination with standard therapies.
Huang et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: